Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.54 |
| ▸ | NPY1R | P25929 | 8/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509136 | 0.96 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RVIPR2 | |
| SCHEMBL29611492 | 0.89 | NPY4R (0.59) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508074 | 0.86 | IL23R (0.55) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL16508142 | 0.85 | KISS1R (0.58) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL16508108 | 0.85 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL17176398 | 0.84 | TFPI (0.57) | KISS1RIL23R | |
| SCHEMBL30782799 | 0.84 | VIPR2 (0.54) | NPY4RNPY5RNPY1RNPY2RVIPR2 | |
| SCHEMBL16507955 | 0.84 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL9437230 | 0.84 | VIPR2 (0.64) | NPY4RNPY5RNPY1RNPY2RVIPR2 | |
| SCHEMBL16507868 | 0.84 | NPY4R (0.58) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | NPY4R 109/4885NPY5R 149/4885NPY1R 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.